Abbott (Abbott Park, IL) is feeling the heat following the completion of its Everest II clinical trial. Results from the trial show that the company’s MitraClip cardiac device doesn’t offer improved efficacy when compared to mitral valve surgery. In addition, patients who received Abbott’s MitraClip required additional operations after implantation. Results of the four-year trial were published in the Journal of the American College of Cardiology. MitraClip is designed for the treatment of mitral valve regurgitation, a condition that can lead to heart failure. The device works by “clipping” parts of a patient’s mitral valve together, improving the heart’s efficiency. The device is designed for implantation through a patient’s femoral artery. Because of this, a patient only requires a small incision in his or her leg for implantation.